11 minutes ago
A phase 2a open-label study found BL-003 for treatment-resistant depression was well-tolerated and any acute effects resolved on average in less than 2 hours.
56 minutes ago
Clinicians and a pharmacist provide an overview of the emerging adalimumab biosimilars in the recent years.
1 hour ago
Dermatologist and rheumatologist Saakshi Khattri highlights the importance of screening psoriasis patients for psoriatic arthritis and how that may impact treatment decisions.
1 hour ago
Drs Lio, Botsoglou, and Axelrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval.
1 hour ago
Experts discuss the plethora of treatment options for psoriasis, including topicals, oral therapies, phototherapy, and biologics.